Home > Boards > US Listed > Biotechs > WuXi PharmaTech Inc. (WX)

Recent quote: "Early work in the NS5A arena

Public Reply | Private Reply | Keep | Last ReadPost New MsgPrevious | Next
UserAlias1 Member Profile
 
Followed By 267
Posts 6,057
Boards Moderated 0
Alias Born 08/22/12
160x600 placeholder
UserAlias1   Tuesday, 01/07/14 11:01:45 PM
Re: None
Post # of 21 
Recent quote: "Early work in the NS5A arena led to the discovery of our first clinical candidate, MK-4882 [2-((S)-pyrrolidin-2-yl)-5-(2-(4-(5-((S)-pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole]. While preclinical proof-of-concept studies in HCV-infected chimpanzees harboring chronic genotype1 infections resulted in significant decreases in viral load after both single- and multiple-dose treatments, viral breakthrough proved to be a concern, thus necessitating the development of compounds with increased potency against a number of genotypes and NS5A resistance mutations. Modification of the MK-4882 core scaffold by introduction of a cyclic constraint afforded a series of tetracyclic inhibitors, which showed improved virologic profiles."

http://www.4-traders.com/news/WuXi-PharmaTech-Cayman-Inc-ADR--Reports-Outline-Biochemistry-Findings-from-WuXi-AppTec--17743221/

Public Reply | Private Reply | Keep | Last ReadPost New MsgPrevious | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences